

Trial Intelligence Report - TS-5621

Protocol Summary

Indication:	General
Phase:	Follow-up Days -28 to -1 Baseline Day 0 Wk 1 Day 7 Wk 4 Day 28 Wk 8 Day 56 W
Sample Size:	108
Duration (weeks):	26
Dropout Rate:	9.1%
Primary Endpoint:	Frequency of moderate to severe adverse events through Week 24 by dosing level, freq

Success Prediction

42.8%

Assessment: Significant risk of failure

Strategic Recommendations

1. Reassess sample size - current value may be insufficient.
2. Consider extending trial duration for more robust outcomes.
3. Implement enhanced participant retention strategies.
4. Review eligibility criteria to ensure appropriate population targeting.

